US Stock MarketDetailed Quotes
IKNA Ikena Oncology
- 1.600
- -0.010-0.62%
Close Jan 8 16:00 ET
77.21MMarket Cap-1.30P/E (TTM)
1.610High1.530Low196.03KVolume1.610Open1.610Pre Close310.21KTurnover1.91%Turnover RatioLossP/E (Static)48.26MShares1.94052wk High0.58P/B16.45MFloat Cap1.22052wk Low--Dividend TTM10.28MShs Float37.610Historical High--Div YieldTTM4.97%Amplitude1.020Historical Low1.582Avg Price1Lot Size
Ikena Oncology Stock Forum
Sign in to post a comment
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on w...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on w...
79
24
19
$Ikena Oncology (IKNA.US)$ They removed my bid from the lit board! Grrrr! Im going to cancel and re bid! Grrrrr
7
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Ikena Oncology (IKNA.US)$ Ikena And Inmagene Enter Merger Agreement; $175M To Support IMG-007 Development, Includes $75M Private Placement; Combined Company ImageneBio To Target Atopic Dermatitis; Expected Close Mid-2025 And Trade On Nasdaq Under The Ticker "IMA"
Benzinga· 3 mins ago
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
The transaction is exp...
Benzinga· 3 mins ago
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
The transaction is exp...
$Ikena Oncology (IKNA.US)$
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology (NASDAQ: IKNA) and Inmagene Biopharmaceuticals have announced a definitive merger agreement, along with a $75 million private placement. The transaction, expected to close in mid-2025, will result in approximately $175 million to support the development of IMG-007, a non-depleting anti-OX40 monoclonal antibody.
The private placement includes investments ...
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology (NASDAQ: IKNA) and Inmagene Biopharmaceuticals have announced a definitive merger agreement, along with a $75 million private placement. The transaction, expected to close in mid-2025, will result in approximately $175 million to support the development of IMG-007, a non-depleting anti-OX40 monoclonal antibody.
The private placement includes investments ...
$Ikena Oncology (IKNA.US)$ I did say 2 weeks ago that data was coming! And they were looking for a possible partner!![]()
2
$Ikena Oncology (IKNA.US)$
Ikena Oncology Announces Strategic Update
Ikena Oncology announced they are discontinuing the development of IK-930, their TEAD1-selective Hippo pathway inhibitor. The company will continue the clinical development of IK-595, a MEK-RAF molecular glue showing promising PK and PD data in RAS and RAF mutant cancers. Ikena ended Q1 with $157.3 million in cash and is projecting $110-$120 million by year-end 2024. The company is exploring strategic options, including part...
Ikena Oncology Announces Strategic Update
Ikena Oncology announced they are discontinuing the development of IK-930, their TEAD1-selective Hippo pathway inhibitor. The company will continue the clinical development of IK-595, a MEK-RAF molecular glue showing promising PK and PD data in RAS and RAF mutant cancers. Ikena ended Q1 with $157.3 million in cash and is projecting $110-$120 million by year-end 2024. The company is exploring strategic options, including part...
1
$Ikena Oncology (IKNA.US)$ They are looking for a licensing partner for one or more of their drugs in pipeline! Also expecting some data release in Q2!![]()
2
$Ikena Oncology (IKNA.US)$ lotto play here !
$Cybin (CYBN.US)$ check out $T2 Biosystems (TTOO.US)$ today with bidens new rules on hospitals battling sepsis t2 is the only fda approved instrument that can catch infections in 3-5 hours that lead to sepsis $Transcode Therapeutics (RNAZ.US)$ $MEDICAL MARIJUANA INC (MJNA.US)$ $Lumen Technologies (LUMN.US)$ $ARMOUR Residential REIT Inc (ARR.US)$ $ZIM Integrated Shipping (ZIM.US)$ $Gritstone Bio (GRTS.US)$ $Turbo Energy (TURB.US)$ $Complete Solaria (CSLR.US)$ $ShiftPixy(Delisted) (PIXY.US)$ $Femasys (FEMY.US)$ $Soleno Therapeutics (SLNO.US)$ $Ikena Oncology (IKNA.US)$ $Iovance Biotherapeutics (IOVA.US)$ $Avalo Therapeutics (AVTX.US)$ $Cybin (CYBN.US)$
5
4
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
SMS1313 : Good sharing![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jaguar8 OP : Green and Red dots because it’s Christmas![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
SMS1313 : Happy Merry Christmas brother![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Gutarie : Merry Christmas
Fox45 : Thanks!
View more comments...